HomeBusinessHealthcare Industry Stock NewsMRK & PFE Earnings: Forecasting The Rest Of 2023 For The Pharmaceutical Industry

MRK & PFE Earnings: Forecasting The Rest Of 2023 For The Pharmaceutical Industry

Merck (MRK) and Pfizer (PFE) recently reported 2Q earnings. MRK's adjusted EPS came in at -$2.06 versus an estimated -$2.17 and revenue came in at $15.04B versus an estimated $14.39B. PFE's adjusted EPS came in at $0.67 versus an estimated $0.57 and its revenue came in at $12.73B versus an estimated $13.17B. Sel Hardy discusses these stocks and forecasts the rest of 2023 for the pharmaceutical industry. CFRA Research expects MRK sales to be roughly flat year-over-year and notes that PFE's Comirnaty and Paxlovid sales guidance for 2023 were unchanged. PFE also narrows FY23 revenue guidance to $67.0B-$70.0B from $67.0B-$71.0B. Tune in to find out more about the stock market today.

Trading 360

01 Aug 2023

SHARE

ON AIR
1:00 pm
The Watch List
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
ON AIR
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
education
7:30 pm
Your First Trade
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Market Overtime
REPLAY
education
9:30 pm
Your First Trade
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now